{"id":"W2275911521","doi":"10.1200/jco.2012.30.15_suppl.559","title":"Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Everolimus; Anastrozole; Hazard ratio; Internal medicine; Aromatase inhibitor; Letrozole; Clinical endpoint; Interim analysis; Progression-free survival; Breast cancer; Oncology; Population; Cancer; Randomized controlled trial; Tamoxifen; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002904848,0.0002033596,0.00182789,0.00008110872,0.00005892403,0.000003468441,0.0002741691,0.0002585684,0.0001015496],"category_scores_gemma":[0.000939713,0.0001082766,0.0002719734,0.0002321748,0.0003966287,0.0002615234,0.00004902825,0.0007118818,0.00000145737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004079884,"about_ca_system_score_gemma":0.00207371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001465127,"about_ca_topic_score_gemma":0.00001452622,"domain_scores_codex":[0.996006,0.0003012936,0.002557894,0.0001902826,0.0004380993,0.0005064172],"domain_scores_gemma":[0.9931341,0.00129602,0.003831521,0.0003515822,0.0009026396,0.0004841676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7281073,0.003443722,0.001023182,0.00002088307,0.000754613,0.0000131883,0.0003289932,0.00004612558,0.002423798,0.0000300295,0.0008234362,0.2629847],"study_design_scores_gemma":[0.7021199,0.06587335,0.05328062,0.0002468354,0.0007891543,0.0007983108,0.0005252707,0.00001677038,0.001248998,0.0001864814,0.1747272,0.0001871293],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984068,0.0007380778,0.0002310404,0.01135407,0.002202441,0.0009641104,0.0001463281,0.00001240012,0.0002834771],"genre_scores_gemma":[0.9916926,0.0002286692,0.002778289,0.002439367,0.002504392,0.00005494687,0.000004285303,0.00003560059,0.0002618204],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2627976,"threshold_uncertainty_score":0.4415391,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07042906341995182,"score_gpt":0.4663861042031853,"score_spread":0.3959570407832335,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}